Embryonic Stem Cell in the Therapy of Neurodegenerative Diseases by Xiaotang Fan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
6 
Embryonic Stem Cell in the Therapy of 
Neurodegenerative Diseases 
Xiaotang Fan1, Yongping Tang2, Kai Wang2, Xiang Cui2,  
Shiqi Tao2 and Haiwei Xu3,4 
1Department of  Histology and Embryology,Third Military Medical University, Chongqing,  
2Department of Physiology, Third Military Medical University, Chongqing, 
3Southwest Hospital, Southwest Eye Hospital, Third Military Medical University, Chongqing, 
4Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, 
1,2,3P.R.China 
4USA 
1. Introduction  
Neurodegenerative diseases comprise a heterogeneous spectrum of neural disorders in 
human and affect millions of individuals worldwide. Although these neurodegenerative 
diseases arise from unknown reasons, their common typical histological feature is the 
occurrence of disease-related cell death in specific regional subpopulations of neurons such 
as the loss of dopaminergic (DA) neurons in the substantia nigra in the Parkinson's disease 
(PD) and loss of medium spiny neurons in the striatum in the Huntington disease(HD), they 
can also possibly affect the diversity neurons and  glial cells such as  the multiple selective 
neurons loss throughout the basal forebrain, amygdala, hippocampus, and cortical  area in 
Alzheimer`s disease (AD) and  dysfunction of supportive glial cells around somatic motor 
neurons in amyotrophic lateral sclerosis (ALS) (Srivastava et al., 2008). Adult central 
nervous system (CNS), different from many other tissues, cannot regenerate and loss of 
mature neural cells is thought to be irreversible. As the increasing of life expectancy in this 
aging society, the neurodegenerative diseases usually cause morbidity and mortality as well 
as increased social and economic burdens of patients and caregivers. Current drugs used for 
treating neurodegenerative diseases provide only limited benefits by alleviating certain 
symptoms, but cannot halt progress of these diseases. In addition, their chronic use is often 
associated with serious side effects (Mangialasche et al., 2010; Kim et al.,2007). Fetal tissue 
and cell transplantation in animal models and patients has pointed to be an alternative 
treatment for these diseases, which can provide neurons to replace lost or degenerated 
neurons, but due to the lack of donor tissues, it will be limited in clinical trials. Promising 
donor cells need to be developed for treating these diseases (Schwarz & Schwarz, 2010;Freed 
et al., 2001; Nishimura et al., 2003). 
Rapid advances in stem cell biology have opened an alternative, fascinating perspective 
treatment for neurodegenerative disease. Stem cells as donor cells used in 
neurodegenerative disease include three different sources:  neural stem cells (NSCs) from 
the embryonic or adult brain, stem cells in other tissues, or embryonic stem cells (ESCs) 
from the fertilized egg (Shihabuddin & Aubert., 2010). 
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Adult progenitor cells from bone marrow or cord blood have been shown to generate 
neurons both in vitro and in vivo studies, although the number of neurons was very low 
(Chua  et al., 2009; Greschat et al., 2008; Bicknese et al., 2002; Song & Sanchez-Romos.,2008). 
The results indicated that stem cells in these tissues would be promising candidates for cell-
replacement therapy due to their accessibility. However, some experiments cannot replicate 
these results, no new neurons production has been observed in these studies, the neural 
differentiation of these stem cells supposed to be artifacts such as occasional cell fusion with 
host neurons appeared in original observations (Rizvanov et al., 2008; Luo et al.,2009). 
Trans-differentiation of adult progenitor cells from bone marrow or cord blood needs more 
evidence to confirm before they used as donor cells in treating neurodegenerative disease. 
NSCs from the embryonic brain have the ability to renew themselves continuously and 
possess pluripotent ability to differentiate into three major CNS cell types, neurons, 
astrocytes, and oligodendrocytes (Reubinoff et al., 2001). Under certain conditions, NSCs 
can also be induced to differentiate into typical neurons such as dopaminergical neurons. 
When transplanted into animal models, embryonic brain-derived NSCs can survive and 
even replace the lost cells caused by brain injury(Goings et al., 2004; Arvidsson et al., 2002). 
But it has indicated that human or rat fetal NSCs or neural precursors(NPs) appeared  to be 
more limited in terms of their differentiation potential, difficult to maintain long-term 
expansion without decline in proliferative and neurogenic capacity (Cao et al., 2002). The 
accessibility to get human fetal NPs also needs to be concerned. In the mammalian adult 
brain including human, NSCs isolated from subventricular zone (SVZ) and hippocampus 
dentate gyrus(DG) have the ability of self-renewing and pluripotency similar to those 
isolated from embryonic brain (Vandenbosch et al., 2009; Jin & Galvan, 2007; Consiglio et al., 
2004; Tropepe, 2007; Okano, 2002). This prompts very promising new strategy to replace lost 
neurons through auto-transplantation, however, it is still stopped due to their uncertainty in 
long-term expansion and reliable differentiation, which will be partially determined by the 
stage of development when NSCs were isolated (Soares & Sotelo, 2004). Meanwhile, to 
increase proliferation rate and decrease the physiological senescence in culture, the 
immortalized cell lines of human NSCs usually were introduced with oncogenes which 
usually resulted in the high risk of transformation (De Filippis et al., 2008). 
ESCs derived from the inner cell mass of blastocysts give rise to various organs and tissues. 
ESCs are able to differentiate into all cell types of ectoderm, endoderm and mesoderm 
(Evans & Kaufman, 1981;Thomson et al., 1998). It has been demonstrated that in vitro ESCs 
can differentiate effectively into NPCs which further differentiate into neurons and glia 
(Tang et al., 2008). The self-renewing and totipotent ability of ESCs have made it an 
intriguing and attractive donor source for cell-based therapies in neurodegenerative 
diseases and brain injury (Reubinoff et al., 2001). Human embryonic stem cells (hESCs) 
usually isolated from early human embryos which makes it encounter ethical risks(Dickens 
& Cook, 2007; Baylis, 2008). However, in 2006, researchers identified conditions of allowing 
some specialized adult somatic cells to be "reprogrammed" genetically to assume a stem 
cell-like state. This new type of stem cell, called induced pluripotent stem cells (iPSCs), 
make it possible to obtain human ESCs without destroying the human embryos (Takahashi 
& Yamanaka, 2006). On the contrary, some studies have suggested that the iPSCs might not 
be an alternative to ESCs, they have different pluripotent ability to turn into different types 
of tissues (Schwarz & Schwarz,2010). Moreover, the first-ever hESCs-based investigational 
new drug (IND) application to treat spinal cord injury has been approved by the U.S. Food 
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and Drug Administration (FDA) in January 2009. It seemed that hESCs could be expected as 
a potential future cell source for cell therapy in neurodegenerative disease.  
AD and PD are the most prevalent kinds of neurodegenerative diseases in ageing people. 
Although not so prevalent, HD and ALS are devasting motor neuron degenerative diseases, 
the patients usually died of this disease shortly after diagnosis (Roze et al., 2010; Perry et al., 
2010).These neurodegenerative diseases share many important commonalities, characterized 
by neuron loss as structural feature. Meanwhile, a different spectrum of cell types is affected 
in these diseases. Therefore, different types of neurons are required for replacement 
(Srivastava et al., 2008). When stem cell transplantation used in these diseases, the strategies 
will vary according to the primary defect of a disease. As above-mentioned, ESCs are 
promising cell source for cell therapy in neurodegenerative disease, recent progress of 
ESCs–based therapies in these diseases is discussed below. 
2. Embryonic stem cell biology 
2.1 Cellular and molecular characteristics of embryonic stem cell    
ESCs were independently first derived from mouse embryos by Martin Evans and Mattew 
kaufman in 1981 (Evans & Kaufman, 1981). This is also the first time to reveal a new 
technique for culturing the mouse embryos in the uterus to allow for an increase in cell 
number, which has been further confirmed by Martin (Martin et al., 1987). In 1998, James 
Thomson firstly developed a technique to isolate and grow hESCs in cell culture (Thomson 
et al., 1998). Later, ESCs have been isolated from other species, including swine, simian, 
monkeys and human blastocysts, but only three species of mammals have yielded long-term 
cultures of self-renewing ESCs namely mice, monkeys and humans (Ohtsuka & Dalton, 
2008). 
Both mouse and human ESCs have the properties of self-renewal and the potential to be 
committed and differentiated in vitro into all three germ layers—namely, ectoderm, 
endoderm, and mesoderm (Murry & Keller, 2008). Both stem cell populations express the 
characteristic markers of undifferentiated cells, including Oct-4(octamer binding 
transcription factor-4), nanog, Sox-2(SRY- related HMG box 2) and utf-1, together with the 
lack of differentiation markers (Sauerzweig et al., 2009). They also express stage-specific 
embryonic antigen-3 and -4 (SSEA-3 and -4), tumor-rejection antigen-1-60 and -1-81, and 
high levels of telomerase activity (Murry & Keller, 2008). ESCs cultures from mouse and 
human are similar in that they grow as colonies of tightly packed cells on inactivated 
murine embryonic fibroblast(MEF) feeders or in conditioned medium(CM) derived from 
such MEFs (Li et al., 2005). The mechanisms by which ESCs from different species maintain 
self-renewal and pluripotency are still not yet fully understood. It seemed that they have 
different mechanisms. Maintenance of mouse ESCs pluripotency in vitro is achieved by co-
culture on irradiated mouse fibroblasts or on gelatinized dishes with a differentiation 
inhibitory factor called leukemia inhibitory factor(LIF) (Cheng et al., 2003). In addition to 
LIF, bone morphogenetic protein 4(BMP4) and the secreted wnt proteins may also 
contribute to maintain ESCs pluripotency (Hiller et al., 2010). Other factors such as Sox2, 
FoxD3 (forkhead box D3)  and  Nanog  can also maintain self-renewal of mouse  ESCs.  
Human ESCs pluripotency is regulated by a combination of extrinsic and intrinsic factors. 
Unlike mouse, extrinsic factors such as fibroblast growth factor(FGF) signaling and a 
balance between transforming growth factor-ǃ(TGF-ǃ)/activin and BMP signaling are 
central to the self-renewal of human ESCs (Xu et al., 2008). Intrinsic factors regulating 
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pluripotency in human ESCs include a battery of transcription factors such as Oct4, SOX2, 
SRY (sex determining region-Y), Box-2 and Nanog (Liber et al., 2010). 
2.2 Embryonic stem cell based transplantation therapy 
ESCs possess several characteristics that make them promising donor cells for 
transplantation therapy in neurodegenerative diseases. When ESCs transplanted into animal 
models which mimic the typical aspects of neurodegenerative diseases, structural and 
functional recovery were also confirmed, although the efficiency were variable. The safety of 
ESCs transplantation is always an important problem to be considered carefully. It has been 
demonstrated  by many studies that ESCs transplantation in the brain tended to form 
teratomas, which is an unacceptable adverse effect for cell transplantation therapy 
(Wesselschmidt et al., 2007). The main strategy to enhance the safety of ESCs for potential 
clinical use is to differentiate the ESCs into neural precursors cells(NPCs) with different 
commitment or mature neurons before transplantation (Shihabuddin & Aubert, 2010). Thus, 
there are two principally different ways of using ESCs for grafting in neurodegenerative 
disease. First, ESCs are pre-differentiated in vitro to specific neurons such as DA neurons 
prior to transplantation in PD, thus, ESCs could become an almost unlimited source for the 
generation of specific neurons. The cell preparations could be standardized and quality-
controlled with respect to viability and purity (Shihabuddin & Aubert, 2010).  The second 
alternative is that the ESCs are induced effectively into NPCs with different commitment, 
which then differentiates in vivo to specific neurons after being implemented into specific 
brain regions.  
 In vivo studies have demonstrated that transplantation of NPCs and neurons derived from 
ESCs are safe and carry no risk of tumor formation, the immunogenic reactivity is also 
relatively low (Cai & Rao, 2007). We argue that long-term survival of new, functionally 
integrated neurons is the main goal to achieve maximum symptomatic relief through stem 
cell therapy. More evidence has confirmed that the observed functional recovery after ESCs-
derived NPCs and neurons were transplanted into animal models of neurodegeneration and 
injury appeared to be related to structural reorganization including synapse formation and 
functional integration (Moghadam et al., 2009; Tang et al., 2008). In the developing brain, 
grafted ESCs-derived neurons developed functional properties of postmitotic neurons 
adopted excitatory and inhibitory neurotransmitter phenotypes and formed synapse with 
host cells (Wernig et al., 2004). In the injured brain regions, grafted ES cell-derived 
precursors differentiated into neurons and exhibited voltage-gated inward and outward 
currents, expressed functional neurotransmitter receptors, and formed synaptic contacts 
(Wernig et al., 2008). Thus, NPCs with different commitment and neurons from ESCs have 
been prospective in CNS repair. 
2.3 NPCs and neurons differentiation potential of embryonic stem cell  
2.3.1 NPCs induction from embryonic stem cell 
NPCs derived from ESCs can be expanded in large numbers for significant periods of time 
and their plasticity potential allows them to differentiate according to the environmental 
cues of host brain (Sakaguchi et al., 2005; Takagi et al.,2005). Getting the NPCs of high purity 
from ESCs is an important step in transplantation research. Evidences from mouse ESCs in 
vitro culture studies have indicated that NPCs can be generated from ESCs and can be 
expanded and differentiated efficiently to neurons and glial cells by serum-free culture 
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(Okabe et al., 1996). The protocol of neural differentiation of ESCs usually involved the 
formation of embryoid bodies(EBs) and the subsequent culture of the attached EBs in a 
selective, serum-free medium to eliminate non-neural cells. Culture of the EBs-derived cell 
pool in this serum-free, selective medium results in a dramatic decrease in cell number, as 
the majority of the cells do not survive under these culture conditions (Lendahl et al., 1990). 
Insulin–Transferrin–Selenium–Fibronectin (ITSF) and N2 serum-free medium have been 
demonstrated to support the selective growth of NPCs (Xu et al., 2004). Considering 
fibronectin increases the neural differentiation of ESCs, offers a tool for growing NPCs as a 
monolayer without impairing their differentiation potential and to generate specific 
differentiated progeny for cell transplantation, we modified the culture medium by adding 
fibronectin (5 μg/ml) in the N2 serum-free selective culture and  found that the number of 
surviving cells was increased significantly when EBs were plated.  After ESCs were cultured 
in this modified NPC-selective medium for 5 days, more than 93% cells were nestin-positive. 
(Xu et al., 2005). The percentage of nestin-positive cells was increased compared with the 
classic method of Okabe, in which the ITSF media was used and the percentage of nestin-
positive cells was 84.1%(Okabe et al.,1996). 
The feasibility of hESCs based cell transplantation in the CNS depends on the generation of 
human neural precursors (hNPs) in vitro. There are several methods for induction of hESCs 
to hNPs, usually rely on EBs formation, stromal feeder co-culture or selective survival 
conditions similar to murine ESCs. Recently, rapid and simple generation of proliferating 
hNPs from feeder free cultures of undifferentiated hESCs has been described. In this 
protocol, hNPs typically expressed neuroectodermal and progenitor markers are derived by 
seeding undifferentiated hESCs on adherent surfaces of laminin or gelatine with normal 
hESCs culturing medium and with the addition of bFGF (Benzing et al., 2006). The process 
of induction of hESCs to hNPs is quite similar to neural induction during embryogenesis. 
Several lines of evidence demonstrate a crucial role for BMP inhibitors including chordin, 
follistatin and noggin as neural inducing factors during neural differentiation of hESCs. It 
seems that the synergistic action of two BMP inhibitors, Noggin and SB431542, are sufficient 
to induce rapid and complete neural conversion of >80% of hESCs under adherent culture 
conditions (Chambers et al., 2009; Pera et al., 2004). In another study, hNPs from hESCs 
produced with a feeder-free system, different media components were compared for the 
efficiency of hNPs generation. Media with N2 produced higher number of hNPs without 
proliferation, media with non-essential amino acids and knock-out serum replacement 
produced fewer number of hNPs with proliferation, and by five passages the culture 
consisted of >97% hNPs. This resulted in an efficient, robust, repeatable differentiation 
system suitable for generating large populations of hNP cells from hESCs (Dhara et al., 
2008).  
2.3.2 Neurons differentiation from embryonic stem cell 
It has been demonstrated that relatively pure of neurons, astrocytes, and oligodendrocytes 
which constitute three major neural cell types of the CNS, can be generated from ESCs 
under appropriate culture conditions (Zhang &Zhang, 2010). Obviously, neuron production 
from ESCs in vitro is similar to neural induction occurred in embryo development, and 
many important factors or signaling pathways have been determined such as ǃ-catenin and 
wnt signaling pathway (Cajánek et al., 2009). In vitro study has indicated that ESCs 
transfected with noggin or exposure to noggin-conditioned medium will enhance neuronal 
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differentiation, while addition of BMP4 strikingly inhibited neuronal differentiation (Zhang 
et al., 2010). Human ES cells can be directed to neurons when exposure to retinoic acid and 
mitogen FGF-2, although selected using cell-sorting methods, the cell population obtained 
after application of this differentiation strategy is still relatively heterogeneous (Guan et al., 
2001). 
Moreover, protocols have been developed for the generation of different subtypes of 
neurons including the sequential combination of regulators. Especially, fetal tissue 
transplantation trials provided important clues for factors inducing typical neurons 
differentiation. For instance, midbrain DA neurons have been generated in the EBs system 
by overexpression in the cells of the transcription factor nuclear-receptor-related factor1 
(Nurr1), and the addition to the cultures of SHH and FGF8 (Lee et al., 2000). Using the co-
culture approach together with the appropriate signaling molecules and selection steps, 
successfully generated cells that display many of the characteristics of motor neurons from 
hESCs (Wichterle & Peljto, 2008 ).  
3. ESCs therapy for neurodegenerative diseases 
3.1 Alzheimer's disease 
AD is a most prevalent kind of dementia and clinically defined as progressive deficits of 
cognition, memory and the ability to live on oneself (Marlatt & Lucassen, 2010). It was 
diagnosed mostly in people over 65 years of age although the less-prevalent early-onset AD 
can occur much earlier (Brookmeyer et al., 1998; Marlatt & Lucassen, 2010). In 2006, there 
were 26.6 million AD sufferers worldwide, the number is predicted to be 1 in 85 people 
globally by 2050 (Brookmeyer et al., 2007). The neuropathology of AD is characterized by 
deposition of insoluble ǃ-amyloid peptides/senile plaques, the intracellular neurofibrillary 
tangles(NFTs)  and the diversity selected neurons loss throughout the basal forebrain, 
amygdala, hippocampus, and cortical  area (Kim & de Vellis, 2009; Whitehouse et al., 1981). 
The etiology and progression of AD are not well understood. It is multi-factorial and 
heterogeneous, which is related with the age, sex, the genotype for apolipoprotein E (Apo 
E), and the sequential proteolytic processing of the amyloid precursor protein(APP) 
(Blennow et al.,2006). Current treatment strategies for AD include targeting cholinergic and 
glutamatergic neurotransmission, moderating the Ǆ-secretase to generate non-toxic ǃ-
amyloid(Aǃ) fragment and delivering NGF into brain which can alleviate symptoms, while  
these  treatments cannot  delay or halt the loss and degeneration of neurons in AD brains 
(van Marum, 2008). Moreover, it has been recognized that the irreversible decline of 
cognitive functions was related to neuron loss in the forebrain cholinergic projection system: 
especially in nucleus basalis of Meynert(nbM) where a massive extracellular deposition of 
Aǃ protein occurs in the later stages of the disease (Boncristiano et al.; 2002; Oliveira & 
Hodges, 2005).  
The development of stem cell biology make it a promising treat approach for AD sufferers 
to restore the lost neurons. Currently stem cell-based therapy for AD is confined to 
preclinical studies on animal models (Sugaya & Merchant, 2008). The effectiveness of several 
stem cells transplantation has been explored and the results are quite similar, sustaining an 
improvement of the mouse’s or rat’s cognitive functions and a general improvement with 
reference to AD pathogenesis hallmarks (Shihabuddin & Aubert, 2010). When cholinergic-
rich tissue and peripheral cholinergic neurons were transplanted into an AD rat model with 
nbM lesions, memory improvement which indicated a partial neuronal rescue has been 
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found in these animal models. However, it is difficult to get enough donor cells, no clinical 
trials in AD patients have been initiated with this method (Fine et al., 1985).  
When ESCs as donor cells transplanted directly in AD animal model, it usually resulted in 
teratomas formation instead of producing neurons (Ringdén et al., 2003; Wang et al., 2006). 
However, ESCs-derived neurospheres, NPCs and neurons transplantation were evaluated 
in animal models and proved to be safe. Wang and colleagues has demonstrated that ESCs-
derived neurospheres transplanted into frontal cortex of Meynert nucleus lesion mouse 
model survived and produced many ChAT-positive neurons and a few serotonin-positive 
neurons in and around the grafts, and the improved working memory was also observed 
after transplantation (Wang et al., 2006). Moghadam and colleagues further implanted 
primed and unprimed mouse ESCs–derived NPCs into the unilateral nbM of rat model of 
AD, Morris water maze and spatial probe test revealed a significant behavioral 
improvement in memory deficits following cells transplantation. Immunohistochemical 
analysis revealed that the majority (approximately 70%) of the NPCs retained neuronal 
phenotype and approximately 40% of them had a cholinergic cell phenotype following 
transplantation (Moghadam et al., 2009). These studies suggest transplantation of mouse 
ESCs-derived NPCs and/or following commitment to a cholinergic cell phenotype can 
promote behavioral recovery in a rodent model of AD. 
Consistent with above studies, we also confirmed that therapy effects of NPCs derived from 
ESCs following transplantation into the rat model of AD. In our studies, we used a derivative 
of the MESPU35 ES cell line that constitutively expresses enhanced green fluorescent 
protein(EGFP), thus allowing us to distinguish between transplanted and host cells. Firstly, we 
investigated the in vivo characteristics of NPCs after differentiation from the ESCs following 
transplantation into the Aǃ-injured dorsal hippocampus of rats. Aǃ-injured rats receiving 
ESCs derived NPCs grafts revealed amelioration of the memory impairment at least 16 weeks. 
Obviously, only live transplanted NPCs can bring about functional recovery, the survival of 
transplanted NPCs in the hippocampus declined with time, while the differentiation rate was 
increased. We found that 9.41% of grafted EGFP-expressing NPCs differentiated into NF-200 
positive cells and 11.31% into GFAP positive cells respectively 4 weeks after transplantation. 
These ratios gradually increased to 40.25% and 19.35% by 16 W. Meanwhile, we also noticed 
that most of the NPCs remained in a cluster and possessed a round morphology that kept 
unchanged over the experimental period, some NPCs were found dorsally along the needle 
tract, a few NPCs had migrated tangentially along the granule cell layer (GCL) in the DG 
region. Of particular note is the fact that these migrating cells within the hippocampus were 
clearly differentiating along a neuronal lineage indicating that the microenvironment can 
support neuronal differentiation, and should be, therefore, also suitable for transplanted 
NPCs. This may overcome the problem of low neuronal differentiation rate of the transplanted 
NSCs in the host brain (Tang et al., 2008). On the other hand, DG of the hippocampus is a few 
region neurogenesis occurred in the adult mammals including primates and humans, and the 
newborn granule cells contribute to processing of learning and memory. Using 
APPswe/PS1DeltaE9 mouse model of AD, we have demonstrated that the cell proliferation in 
the DG of AD was declined significantly (Li et al., 2008), meanwhile increased hippocampus 
neurogenesis contributes to memory function recovery has been reported in many studies 
(Duan et al., 2008; Mohapel et al., 2006). Therefore, NPCs transplantation in the DG of 
hippocampus, maybe a new promising therapeutic strategy of AD compared with dorsal 
hippocampus transplantation.  
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To confirm this hypothesis, in our recent study, injection of a toxic fragment of Aǃ 1–40 into 
the upper leaf of DG was used to make an in vivo, AD-like rat model. Selective loss of 
granular neurons mainly observed in the upper leaf of the DG near the injection site, which 
is consistent with the results of Reyes(Reyes et al., 2004). Similar to our previous finding that 
NPCs derived from ESCs grafted into dorsal hippocampus, the spatial learning and memory 
were improved in animals with NPCs transplantation into DG of the hippocampus(Tang et 
al., 2008). After transplantation into Aǃ1-40-injured rats, ESCs-derived NPCs survived up to 
12 weeks and migrated along the upper leaf of the DG, where granular cells were 
degenerated and lost. We further demonstrated that grafted cells differentiated well in the 
DG of the hippocampus as seen by checking neuronal and glial markers after 
transplantation. In addition, it showed that these incorporated donor neurons exhibited a 
broad spectrum of neuronal morphologies ranging from simple bipolar to complex 
multipolar phenotypes. Meanwhile, the abundant labeled glutamatergic and GABAergic 
neurons were seen in 8 and 12 weeks after grafting, donor neurons also expressed proteins 
essential for synaptic transmission, including the major subunits of ionotropic glutamate 
and GABA receptors (NR1, GluR1) and GABAA receptor ǃ-chain, respectively(Li  et al., 
2010).  
Numerous reports point out that the therapeutic effect mediated by the transplanted cells in 
various neurological disorders depends on the functional integration of transplanted cells 
into brain circuits upon in vivo differentiation into mature cells (Maroof et al., 2010; 
Aldskogius et al., 2009; Reubinoff et al., 2001). To testify the possibility of integration of 
ESCs derived neurons in the hippocampus of AD rats, the synapse formation between 
donor neurons and host neurons were demonstrated by PSD-95-positive puncta and 
synaptophysin positive puncta. The density of PSD-95 and synaptophysin positive puncta 
showed higher level at 12 weeks post transplantation compared with 8 weeks. This was 
further confirmed using Qtracker® Cell Labeling technique, that is, the engrafted cells were 
pre-labeled by Quantum dots (QDs) before cell transplantation which makes them visible 
under bright field, fluorescence field and electron microscopy(EM), they formed typical 
ultrastructure of post-synaptic or pre-synaptic connections with host neurons following 
transplantation when observed under EM. Our study directly showed that synapse 
formation between host and donor neurons, which provided morphological evidences for 
the reconstruction of damaged hippocampal neuronal networks in AD by cell 
transplantation (Li et al., 2010). Many studies have demonstrated that the grafted cells 
effectively signal to the host and vice versa by electrophysiological demonstration, for 
instance, paired recordings as the most stringent criteria for functional integration and 
crosstalk between host and graft. C-fos as another good candidate for the initial steps of 
learning inducing long term synaptic plasticity, we found that, after behavioral training, 
there was an increase in the percentage of co-localization of Fos and EGFP in hippocampal 
DG of Aǃ1-40-injured rats compared to that in rats with stationary stimulation. This indicates 
an involvement of the engrafted neurons in the circuitries contributing to learning and 
memory (Li et al., 2010). 
Therefore, the effectiveness of these ESCs transplantation is quite similar, sustaining an 
improvement of the animal’s cognitive functions and promising reconstruction of structural 
and function (Sugaya et al., 2007; Sugaya et al., 2006; Sugaya, 2005; Marlatt & Lucassen, 
2010; Taupin, 2009). Since the neuropathological changes of AD is too widespread 
throughout the brain, it seems very difficult to decide the place for grafting and the dosage 
of cells, this makes the cell transplant therapy more difficult than that of single brain site 
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impact diseases like PD and HD (Imitola, 2007). Based on our study, DG is a promising site 
for grafting NPCs derived from ESCs, the long term recovery evaluation at structure and 
function level needs to be explored in the future. 
As Aǃ deposition is a hallmark of AD, the effect of Aǃ on the survival, migration and 
differentiation of grafted cells is the major factor deserves to be taken into consideration. 
Sugaya reported that human NSCs transplanted into the brain of APP transgenic mouse 
exhibited less neurogenesis and active gliosis around the plaque like formations, while 
using a well-defined in vitro culture differentiation model of NSCs, it found that APP is 
necessary for the migration and differentiation of NSCs, suggest APP level can regulate 
NSCs biology, the changes of APP metabolism in AD will cause the deficiency of grafted 
stem cells (Sugaya & Brannen, 2001; Sugaya et al., 2006). It reported recently that the APP is 
expressed by human ESCs, and the differential processing of APP regulates the proliferation 
and differentiation of ESCs. The exogenously added soluble and fibrillar APP significantly 
reduces the proliferation of ESCs and increases the NPCs differentiation (Porayette et al., 
2009). It was reported that human NSCs exposed to high concentrations of secreted 
amyloid-precursor protein (sAPP) in vitro differentiated into mainly astrocytes, suggesting 
that pathological alterations in APP processing in AD may prevent neuronal differentiation 
of NSCs (Marutle et al., 2007; Kwak et al., 2010). Thus, successful cell transplantation 
therapy for AD may require regulating APP expression to favorable levels to enhance 
neuronal differentiation of NSCs at the same time. 
3.2 Parkinson’s disease 
PD is the second most common neurodegenerative disorder, clinically characterized initially 
by muscle rigidity, resting tremor, and slowing of movement. Over time, patients sustain a 
loss of mobility and dysautonomia, dystonic cramps and dementia (Jankovic, 2008). The 
common pathological features in PD patients are degeneration of DA neurons in the 
midbrain and diminished dopamine in the striatum, which normally receives substantia 
nigra (SN) dopamine inputs (Kish et al., 1988; Agid, 1991). The vast majority of cases are 
sporadic, and some of these are caused by mutations in ǂ-synuclein, parkin, UCHL1, DJ1, 
PINK1, and LRRK2 , with a Mendelian pattern of inheritance (Hardy, 2003). All current PD 
therapies focus on restoring the dopamine levels by either the oral administration of the 
dopamine precursor levodopa (L-DOPA), which supplements the low level of endogenous 
dopamine, or inhibition of the breakdown of endogenous dopamine by treatment with the 
monoamine oxidase type B (MAO-B) inhibitor, selegiline (Hardy, 2003). Dopamine agonists 
are also used to directly stimulate the dopamine receptors. Unfortunately, these therapies 
are all symptomatic treatments, they do not prevent the progress of the DA neuronal 
degeneration and, more importantly, are not capable of curing PD. In the later stages of this 
treatment, L-DOPA becomes ineffective or, even worse, causes severe side effects, such as 
the development of dyskinesias (Fahn et al., 2004; Lang & Lozano, 1998 a,b). Surgical 
treatment by deep brain stimulation is practiced to further modify dyskinesias. Although 
advanced, this treatment does not stop the progression of the disease either, therefore there 
is a great need to develop new regenerative therapeutic strategies that directly target the 
degenerating DA neurons or their innervation areas (Walter & Vitek, 2004). 
 Cell transplantation from fetal tissues has offered some success in the treatment of 
Parkinson's disorder, but is limited by the difficulty of obtaining the tissues for 
transplantation (Lindval et al., 1990; Olanow et al., 1996; Kordower et al., 1997; Dunnett & 
Björklund, 1999). Extensive in vivo animal studies have shown that fetal ventral 
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mesencephalic (VM) grafted into rats striatum of PD models produced marked recovery 
from amphetamine induced rotational asymmetry. The grafts could survive in host 
striatum, restore the damaged nigrastriatal pathway and release dopamine (Perlow et al., 
1979; Freund et al., 1985). Based on these experimental data, clinical trials with 
transplantation of fetal VM into patients were initiated in 1987, and transplantation efficacy 
has been shown in open-label trials without post-operative complications. Fetal VM 
transplantation seems to be promising in treating PD, and the clinical benefits have been 
reported in early clinical trials (Lindvall et al., 1989). However, outcomes following 
transplantation of fetal VM in PD patients were variable. In the best cases, DA neurons 
survived, released dopamine and the major clinical improvement could last for up to 6 to 12 
years post-surgery (Piccini et al., 1999). On the other hand,  two NIH-sponsored, double-
blind clinical trials had found that some patients failed to show behavioral recoveries 
observed in the previous open-label trials and suffered graft-induced dyskinesias, probably 
caused by the grafts’ excessive and uncontrolled proliferation and release of dopamine 
(Björklund, 2005; Winkler et al., 2005). Although the disparity in the outcome from clinical 
trials is not clear, probably is related to many factors, including the age of the donor tissue, 
the severity and stage of the disease and the difference in immunosuppressant treatment in 
patients. The variable results from clinical trials, together with the lack of donor tissues and 
standardization of protocols have led to re-evaluation of the use of such tissue for further 
transplantation into humans. In this regard, human ESCs could be a potential future 
alternative cell source for cell -replacement therapy for PD.  
It is necessary for transplanted cells to synthesize dopamine and to control release, reuptake, 
and metabolizing dopamine, as the original DA neurons to treat PD. There are two principal 
different ways of using ESCs pre-differentiated into DA neurons and stem or progenitor 
cells with different commitment transplanted into the striatum or SN. Mouse ESCs 
transplanted into adult mouse brain and kidney capsule developed large numbers of cells 
exhibiting neuronal morphology including DA neurons. TH positive axons from 
intracerebral grafts grew into regions of the dopamine-lesioned host striatal gray matter 
(Kleppner et al., 1995; Morassutti et al., 1994; Wojcik et al., 1993; Miyazono   et al., 1995; 
Isacson & Deacon 1996; Hemmati-Brivanlou & Melton, 1997). Then a further study in which 
with low numbers of undifferentiated mouse ESCs implanted into the rat DA-depleted 
striatum, the cells proliferated and differentiated into functional DA neurons that reduced 
Parkinsonism (Björklund  et al., 2002). However, lethal teratomas developed in 20% of the 
animals. More studies have reported that transplantation with NPCs in vitro differentiated 
from ESCs could decrease the possibility of teratomas formation (Björklund et al., 2002). 
Highly enriched populations of NPCs were developed in vitro from mouse ESCs and then 
implanted into Parkinsonian rats. The engrafted cells led to the recovery from Parkinsonism, 
and teratoma formation was not observed (Geeta et al., 2008). We also demonstrated that 
NPCs derived from MESPU35 mouse ES cell line grafted into the striatum of PD rats 
produced therapeutic effect evaluated with rotation test. The number of survival NPCs was 
increased significantly by fibronectin and over 90% of the engrafted NPCs were TH-positive 
6 weeks after transplantation into the striatum of PD rats (Xu et al., 2004). There are no signs 
of tumor growth or non-neural tissue formation in the transplant recipients. It seemed that 
uncommitted mESC-derived NPCs could differentiate into DA neurons in host brain after 
transplantation, thereby leading to functional recovery (Kim et al., 2002). On the contrary, 
Ben-Hur et al has noticed that transplantation of uncommitted hESC-derived NPCs induced 
partial behavioral recovery, while there is no detectable DA neurons from grafted NPCs. 
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The disparity may lie in the different biological characters of hNPCs compared to NPCs 
from mESCs when drived to DA differentiation (Ben-Hur  et al., 2006). Ben-Hur et al has 
developed a simple protocol to harvest hNPCs from hESCs expressing transcripts of key 
regulatory genes of midbrain development, as well as markers of DA neurons, supporting 
their potential to differentiate into midbrain DA neurons. When these hNPCs grafted into 
the striatum of Parkinsonian rats, they survived for at least 12 weeks and differentiated in 
vivo into DA neurons. Transplanted Parkinsonian rats also exhibited significant behavioral 
recovery (Ben-Hur et al., 2006). Hence, induction of hNPCs differentiation toward a 
midbrain fate prior to transplantation is probably required for complete correction of 
behavioral deficit. In this regard, the host tissue probably could not direct the transplanted 
uncommitted hESC-derived NPCs to acquire a dopaminergic fate. The partial functional 
recovery induced by transplantation of uncommitted hESC-derived NPCs maybe due to the 
'trophic' support provided by undifferentiated grafted cells within the damaged tissue (so 
called 'bystander effect'). 
Although NPCs might have greater developmental plasticity to respond to host 
environmental inductive cues that guide DA neuron differentiation, the adult striatum is 
probably unlikely to retain all instructive signals for DA neuron development from these. 
Therefore, pre-differentiation of ESCs into neural cells of a certain maturation stage is a 
prerequisite for obtaining a larger number of graft-derived DA neurons. It has been 
confirmed that ESCs-derived neurons carrying features of the ventral midbrain 
dopaminergic SN neurons will express En1, Pitx3, Nurr1, Lmx1b and Girk2, and will be  
labeled with dopaminergic markers, such as the dopamine transporter, vesicular 
monoamine transporter and the enzyme aromatic amino acid decarboxylase (Wernig et al., 
2008). Signaling factors involved in CNS development have been used to control the 
differentiation of ESCs into mesencephalic dopamine (mesDA) neurons (Ye et al., 1998). 
Studies have used neurotrophic factors and overexpression of midbrain-specific genes to 
induce a dopaminergic phenotype in mouse ESC-derived neurons (McKay et al., 2006). It is 
well known that Shh, FGF8, Wnts affect the local environment in which mesDA neurons are 
generated during embryogenesis. However, these molecules underlie the regional 
specification of several cell types generated in midbrain (MB) and hindbrain during CNS 
development (Ling et al., 1998; Potter et al., 1999; Storch  et al., 2001; Hynes & Rosenthal 
1999; Wurst & Bally-Cuif,2001; Lee et al., 2000; Horiguchi et al., 2004) . As a consequence, in 
addition to mesDA neurons, cultures also include other regionally related neuronal 
subtypes such as serotonergic and GABAergic neurons (Deacon et al., 1998). Importantly, 
when used in cell therapy, some of these contaminating neuronal types may cause 
unwanted side effects after grafting. Thus, heterogeneity complicates development of a 
therapeutic application of stem cells and emphasizes the importance of developing methods 
that can generate highly enriched cultures of mesDA neurons. It is crucial to identify the 
fate-determining regulatory factors that influence dopamine cell fate decision and the 
underlying molecular machinery.  
Neurotrophic factors and overexpression of midbrain-specific genes have been used to 
induce a dopaminergic phenotype in mouse ESCs-derived neurons. In vitro studies have 
shown that Shh, FGF-8, ascorbic acid, TGF-ǃ and cyclic AMP all increase the differentiation 
of DA neuron in culture (Ye et al., 1998). One of the most effective inducers of a 
dopaminergic fate comes from stromal-derived inducing activity from co-culture with 
stromal cell lines such as PA6 and MS5 (Kawasaki et al., 2000). It will be important to define 
the specific developmental stage of such committed precursors that will result in optimal 
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survival, functional integration, and behavioral effects. A great deal of progress has been 
made in recent years in identifying transcription regulators that control the specification, 
migration and functional maintenance of mesDA neurons, providing insight into the 
generation of these cells in vitro and in vivo(Kim et al., 2002; Andersson et al., 2006). 
Researchers have over-expressed genes and transcription factors such as Nurr1, Pitx3 and 
Lmx1a known to promote the development of midbrain DA neurons resulting in much 
higher yields of DA neurons in vitro and in vivo (Kim et al., 2003; O’Keeffe  et al., 2008; 
Chung  et al. ,2005) 
For DA neuron production from ESCs, genetic manipulation of transcription factors is by far 
the most effective approach. However, it is still in question how  typical active ventral 
midbrain cell population contributes to functional reconstitution in PD brain. It can be 
determined by systematic transplantation studies using purified, molecularly defined cell 
populations from the developing midbrain. Studies on normal development of the midbrain 
DA lineage can help to analyze the molecular make up of cells at each step of DA lineage 
differentiation. It will be promising to determine the desired ‘donor’ cells for PD treatment 
from heterogeneous populations of differentiated ESCs progeny.  
3.3 Huntington’s disease 
HD is a fatal hereditary and neurodegenerative disease characterized by involuntary 
choreiformic movements, cognitive impairment, and emotional disorder. In United States, 
there are nearly 30000 HD patients and 150000 are in high risk (Leegwater-Kim & Cha, 
2004). HD is caused by mutation of a gene, which resulted in an abnormal expansion of 
CAG-encoded polyglutamine repeats in a protein called huntingtin (Walker, 2007). The 
presence of huntingtin leads to the loss of medium spiny neurons(GABAergic neurons) in 
the striatum, and to a lesser extent, in other extrapyramidal and cortical areas(Melone et al., 
2005). Current pharmacotherapies of HD have been evaluated targeting the 
neurotransmitters such as GABA, dopamine, glutamate which are regarded as  the 
predominant neurotransmitters affected in HD, however, few well conducted trials for 
symptomatic or neuroprotective interventions have yielded positive results. There is no 
current method to change the course of HD (Frank & Jankovic, 2010).  
Since the hallmark of HD is the loss of some specific neurons in the striatum and other 
regions in the brain, cell transplantation may serve as a hopeful strategy for reducing neural 
damage and replacing the lost neurons in the HD brain (Bachoud-Lévi  et al., 2000; Dunnett 
& Rosser, 2007; Kim et al., 2008; Clelland et al.,  2008; Schwarz & Schwarz, 2010). As early as 
1983, Deckel et al transplanted fetal rat striatal tissues fragments into the KA-injured 
striatum and behavioral improvement was reported (Deckel et al., 1983).  In 1995 Isacson et 
al transplanted embryonic porcine neural cells into adult rat brains with neuronal and 
axonal loss typical of HD, and found donor axons in host white matter tracts sprouting a 
long distance from transplant sites, it demonstrated that adult host brain can orient growth 
of transplanted neurons in cellular repair of the mature CNS (Isacson et al., 1995). This 
directly proved that transplanted xenogeneic neural cells in neurodegenerative disease 
models exhibit remarkable axonal target specificity and distinct growth patterns of glial and 
axonal fibers. Subsequently, numerous cellular therapy in excitotoxic striatal lesion HD 
animal models were reported, these transplantation experiments were carried out in HD 
animal  models  including mice , rats and monkeys (Bernreuther et al., 2006; Isacson et al., 
1989). The transplanted cells derived from embryonic striatal tissues can survive and 
differentiate into the cell types of the normal striatum, the behavioral performance of the 
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HD models were also improved (Bernreuther et al., 2006; Emerich et al., 1998). However, in 
transgenic mice, the authentic HD animal model, striatal cell transplantation only produced 
a limited effect on behavioral function (Gutekunst et al.,2000).  
The clinical study of cell-based therapy on HD was conducted in Mexico in 1990, after that 
several reports from several countries showed that the human fetal striatal transplants could 
survive in the striatum without displacing the surrounding tissue (Gallina  et al.,2010; 
Capetian et al., 2009; Hauser et al., 2002). Furthermore, human fetuses from ganglionic 
eminences (GE) transplanted into patients had shown long-term success (Bachoud-Lévi  et 
al., 2006; Bachoud-Lévi et al., 2000). The striatal tissues and GE used in these cell-based 
treatment were isolated from the spontaneously aborted fetuses or selective abortions. The 
ethical and social issues of using human fetal tissues are still the major obstacles in the cell 
based replacement in HD. 
 ESCs have the potential to divide indefinitely in culture, producing unlimited cell source 
for cell-based therapy, which is considered as a major advantage. The production of NPCs 
from ESCs is the practical strategy of ESCs based cell transplantation for HD (Song  et al., 
2007; Bosch et .,2004; Bernreuther et al., 2006). Song and colleagues differentiated hESC into 
hNPs  by co-culturing with PA6 stromal cells, and subsequently transplanted them into the 
striatum of quinolinic acid(QA)-induced HD model (Song et al., 2007). The transplanted 
animals exhibited a behavioral recovery for 3 weeks after transplantation (Song et al., 2007). 
It suggested that hESC-derived hNPCs can lead to a behavioral recovery, as well as 
neuronal differentiation in HD model. However, hESC-derived hNPCs differentiated into 
limited number of GABAergic neurons in this way, which is selected death in HD. One 
research group has generated a homogenous population of functional GABAergic neurons 
from a NSCs line, using retinoic acid and potassium chloride depolarization (Bosch et al., 
2004). When transplanted in the QA model, these cells survived and improved functional 
deficits in vivo (Bosch et al., 2004). Restoring the lost brain functions by replacing damaged 
striatal neurons will be a crucial step to develop efficient cell replacement therapy in HD. 
  Recently, several protocols have been developed to produce striatal medium-spiny 
GABAergic neurons. L1-transfected mESCs cell line generated by Bernreuther et al showed 
decreased cell proliferation in vitro, enhanced neuronal differentiation in vitro and in vivo. 
Mice grafted with NPCs derived from L1-transfected ESCs showed functional recovery as 
decreasing rotation behavior 1 and 4 weeks post-transplantation and increased yield of 
GABAergic neurons and enhanced NPCs derived from ESCs migration into the lesioned 
striatum (Bernreuther et al., 2006). Thus L1 overexpression in the ESCs provides an efficient 
way to get striatal medium-spiny GABAergic neurons to treat HD. In one recent study, 
mESC line transfected with the extracellular matrix molecule tenascin-R (TNR), which is 
expressed by striatal GABAergic neurons, showed enhanced differentiation into neurons in 
vitro, reduced migration in vitro and in vivo (Hargus et al., 2008). Mice grafted with NPCs 
generated from TNR-transfected ESCs produced more GABAergic neurons and less 
astrocytes in grafts 1 month and 2 months after transplantation into the QA-treated 
striatum. Moreover, TNR-overexpressing ESCs transplanted into the striatum attracted host-
derived neuroblasts from the rostral migratory stream and promoted recruitment of host-
derived newborn neurons within the grafted area (Hargus et al., 2008). These indicated that 
both L1 and TNR guide ESCs to differentiate to GABAergic neurons, although they share 
different mechanism. It is likely that a combination of different molecular cues including 
recognition molecules, neurotrophic factors, and extracellular matrix molecules with cell 
transplantation will lead to at least additive effects on functional recovery in HD treatment.  
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In another study, Aubry et al has designed an in vitro protocol to push hESCs along the 
neural lineage, up to postmitotic neurons that exhibit phenotypic features of the medium-
spiny GABAergic neurons (MSNs) of the striatum (Aubry et al., 2008). hESCs-derived 
striatal progenitors have been shown efficiency differentiation into striatal GABAergic 
neurons following xenotransplantation into adult rats. Such these hESCs-derived striatal 
progeny may provide a potential cell therapy product to substitute for fetal neural 
precursors that are currently used in clinical trials to treat patients with HD. On the other 
hand, apparent overgrowth of human xenograft in rat brain was observed, the hyperplasia 
of grafted ESCs derived NPCs in the brain should take into account. Vazey et al reported 
that excessive proliferation was observed in the brain of HD rats in the spontaneously-
induced hNPCs group 8 weeks post-transplantation (Vazey et al., 2006). Similar result has 
also been reported in a recent study when using MS5 stromal-induced hNP to graft into the 
QA lesioned striatum, significant numbers of transplant-derived overgrowths could not be 
identified until eight weeks post-transplantation. Vazey et al further demonstrated that 
noggin-primed hNPs have a greater capacity to survive long-term and differentiate into 
neurons than spontaneously-derived hNPs after transplanted into the striatum of QA-
induced HD model (Vazey et al., 2010). In addition, hyperplasic growths and aberrant 
differentiation were efficiently controlled by noggin-primed hNPs transplantation even up 
to 8 weeks post transplantation, which suggested that noggin-primed hNPs transplantation 
provides an effective and safe  treatment for HD.  
3.4 Amyotrophic lateral sclerosis  
ALS, also known as Lou Gehrig`s disease, is an adult-onset neurodegenerative disorder 
characterized by the gradual degeneration and death of motor neurons in the cerebral 
cortex, brain stem and spinal cord. The loss of motor neurons in the long run resulted in 
progressive paralysis and death within two to five years after diagnosis. The vast majority of 
ALS cases are sporadic (sALS), while approximately 5-10% of cases are inherited (known as 
familial; fALS) (Gros-Louis et al., 2006). Mutation in genes including cytosolic Cu/Zn 
superoxide dismutase (SOD1), alsin, senataxin, synaptobrevin/VAMP (vesicle-associated 
membrane protein-associated protein B) and dynactin have been reported to cause fALS 
(Rosen et al., 1993; Yang et al., 2001; Hadano et al., 2001; Chance, 1998; Chen et al., 2004; 
Nishimura et al., 2004). Transgenic rodents carrying mutant human SOD1 genes appear 
many of the clinical and neuropathological features of familial as well as sporadic ALS, 
seem to be one useful model of the disease for preclinical studies. Several mechanisms are 
possibly involved in the etiology of motor neuron degeneration in ALS such as glutamate 
excitotoxicity, impaired axonal transportation, protein misfolding, cytoskeletal 
abnormalities and exposure to toxic or infectious agents. Currently, many evidences have 
shown that the activation and proliferation of astrocytes and microglia appeared common in 
ALS are regarded as another possible cause for motor neuron degeneration in ALS (Barbeito 
LH et al., 2004). Riluzole (Rilutek) is the first FDA-approved medicine for ALS, used to 
reduce motor neurons damage by decreasing the release of glutamate, which only prolongs 
patient survival by several months (Gurney et al., 1998). Other potential therapies for ALS,  
which partially alleviated symptoms has been shown in human clinical trials. So far, there is 
no effective treatment to cure the patients suffering from ALS. 
As the lack of effective drug treatments and the typical pathological changes of ALS are the 
degeneration and loss of motor neurons in the CNS, cell replacement is considered as a 
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promising treatment strategy. Xu and colleagues used NSCs from human fetal spinal cord in 
the transplantation experiments of SOD1 transgenic ALS rats (Xu  et al., 2006). The grafted 
hNSCs were found to differentiate into neurons and formed synapse, secreting several 
neurotrophic factors, and the degeneration progression of motor neurons in this ALS model 
was delayed (Xu  et al., 2006). It suggested that NSCs grafts can survive well in a ALS 
environment and the functional improvement was partly caused by the motor neuron 
growth factors released by grafted NSCs. Intrathecal transplantation of immortalized 
human NSCs overexpressing vascular endothelial growth factor(VEGF) gene was also 
reported to  significantly delay the onset and prolonged the survival of the SOD1G93A 
mouse model of ALS. By concomitant downregulation of proapoptotic proteins and 
upregulation of antiapoptotic proteins, the transplanted human NSCs provided 
neuroprotective effect in the spinal cord of ALS (Hwang et al., 2009). Recently Mitrecić and 
colleagues compared the efficiency of NSCs delivery to the CNS in ALS at different stages 
and found that NSCs via intravenous tail vein injections  enter the CNS affected by 
inflammation/degeneration, the highest delivery efficiency was found in symptomatic ALS  
and moderate in presymptomatic ALS, while the lowest in wild-type group (Mitrecić et al., 
2010). The grafted NSCs preferentially localize in the motor cortex, hippocampus, and spinal 
cord. 
Considering the human NSCs usually isolated from fetal spinal cord or brains, the ethics 
obstacles make it unsuitable in clinical application. ESCs as totipotent cell are able to 
differentiate into motor neurons under defined conditions (Nizzardo et al., 2010 ; Li et al., 
2008; Soundararajan et al.,2007). Evidences have shown that developmentally relevant 
signaling factors such as retinoid acid (RA) and sonic hedgehog (Shh) can induce mouse 
ESCs to differentiate into spinal progenitor cells, and subsequently into motor neurons (Hu 
& Zhang, 2010; Kim et al., 2009; Li et al., 2008). When transplanted into embryonic chick or 
adult rat spinal cords, ESCs cell-derived motor neurons can populate the embryonic spinal 
cord, extend axons, and form synapses with target muscles (Goldstein, 2010). In the similar 
approaches used for mouse ESCs with small modification, it has been successful in 
generation of spinal motor neurons from human ESCs in an adherent culture. In terms of the 
initial neural induction, human ESCs, require FGF2 or those generated from co-cultured 
feeder cells, then treated with a combination of Shh and RA to generate spinal motor 
neurons efficiently (Hu & Zhang, 2010). The in vitro–generated motor neurons from  human 
ESCs expressed HB9, HoxC8, choline acetyltransferase and vesicular acetylcholine 
transporter, form synapses on co-cultured myoblasts/myotubes and are 
electrophysiologically active(Li et al., 2005). These indicate that ESCs are promising donor 
cells for supplying motor neurons. High purified generation of motor neurons can improve 
safety, due to decreased number of cells for transplantation. Most recently, Li has described 
a simple chemically defined suspension culture generated 50% efficiency of motor neuron 
differentiation from human and primate ESCs treated with purmorphamine, a small 
molecule that activates the Shh pathway (Li et al., 2008). Furthermore, stable transfection of 
human and mouse ESCs with Hb9 promoter-driven green fluorescent protein genes, 
followed by a further isolation of the green cells by fluorescence-activated cell sorting 
(FACS), could  generate enrichment of the motor neuron population from ESCs (Giudice & 
Trounson, 2008). 
In vivo studies, ESCs are seemed to be promising cell sources of cell based treatment of ALS. 
The study reported that the expression of Hb9 could directly induce mouse ESCs into 
cholinergic motor neurons. When transplanted into the spinal cord, these ESCs-derived 
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motor neurons were observed to extend the axons and form synapses with muscles (Giudice 
& Trounson, 2008). Domos and colleagues had generated iPSCs from an 82-year-old with 
familial ALS woman and successfully directed to differentiate into motor neurons. These 
patient-specific iPSCs possess properties of ESCs and supposed to be used in the cell 
transplantation of ALS (Dimos et al., 2008). Recently, López-González et al differentiated 
mouse ESCs into motor neurons and grafted into the lumbar spinal cord of hSOD1(G93A) 
ALS rats. They found that grafted cells with motor neuron phenotype can survive for at 
least 1 week in hSOD1(G93A) animals and the significant improvement in movement was 
transiently recovered, However, the long-term effect of cell transplantation was not 
guaranteed because the transgenic hSOD1(G93A) environment is detrimental to grafted 
motor neurons (Lopez-Gonzalez et al., 2009). 
Glial cells such as astrocytes and microglias create a hostile environment that contributes to 
motor neuron toxicity in transgenic ALS animal models and then may also adversely affect 
the survival and maturation of transplanted stem cell derived-motor neurons. Makiko has 
demonstrated that rodent astrocytes expressing mutated SOD1 kill spinal primary and 
mouse ESCs–derived motor neurons without leading to the death of spinal GABAergic or 
dorsal root ganglion neurons or ESCs–derived interneurons (Nagai et al., 2007). Conversely, 
expression of mutated human SOD1 in primary mouse spinal motor neurons does not 
provoke motor neuron degeneration (Nagai et al., 2007). These findings suggest that 
astrocytes may play a role in the specific degeneration of spinal motor neurons in ALS.  
Marchetto et al co-cultured human ESCs-derived motor neurons with human primary 
astrocytes expressing mutated SOD1 and found that a selective motor neuron toxicity was 
correlated with increased inflammatory response in SOD1-mutated astrocytes (Marchetto et 
al., 2008). Consistent with this study, it has been confirmed that human ESCs-derived motor 
neurons are selectively sensitive to toxic effect caused by astrocytes carrying an ALS-causing 
mutation in the SOD1, while interneuron populations produced from ESCs are unaffected 
(Di Giorgio et al., 2008). Taken together, these studies suggest a scenario in which mutation 
of SOD1 activates inflammatory pathways in astrocytes, including activation of 
prostaglandin D2(PGD2) signaling and nitric oxide release. Furthermore, primary motor 
neurons co-cultured in direct contact, particularly with primary mutant SOD1-expressing 
microglia, showed decreased survival and shortened neurite length (Zhao et al., 2010). As 
further evidence for microglial toxicity to motor neurons in ALS, several studies have 
indicated that isolated primary microglia become toxic to primary motor neurons when 
activated with either proinflammatory LPS or IgG immune complexes isolated from human 
ALS patients (Thonhoff et al., 2009; Weydt et al., 2004; Dewil et al., 2007). 
Different from other neurodegenerative diseases, both the motor neurons and non-neuronal 
cells (mainly astrocyte or microglial) should be taken into account in the stem cell 
replacement of ALS. When using ESCs transplantation treating ALS, the replacement of 
dysfunctional non-neuronal glial cells such as astrocytes and microglia will be helpful to 
protect motor neurons. 
4. Prospects and conclusions  
Although ESCs transplantation has been proved to be a promising tool and potential 
therapies for treating incurable neurodegenerative diseases such as AD, PD, HD, and ALS, it 
is too early to be optimistic that ESCs will be used immediately clinically to cure the 
neurodegenerative diseases. Several issues about safety, effectiveness, ethical and feasibility 
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must be considered before the adoption of stem cell replacement is widely accepted in 
clinical medicine. The risk of tumorigenesis is primary consideration of ESCs replacement in 
patients suffered from neurodegenerative diseases. The small number of ESCs escape 
differentiation and selection procedure may over proliferate and bring the risk of teratoma 
formation (Rao, 2007).With development of procedures to produce high purified NPCs with 
commitment and mature neurons derived from human ESCs is safe in cell transplantation of 
neurological diseases. It has been achieved to generate enrichment neuron or NPC 
populations from ESCs, while the efficiency to produce more specific neuron such as DA 
neuron is very low. It maybe overcomed by uncovering the developmental mechanism and 
improved techniques (Cho et al., 2008). It seemed effective when ESCs were used in the 
transplantation experiments in the animal models of neurodegenerative diseases, but the 
long term effects related to security and recovery of structure and function need to be 
evaluated carefully before clinical practice. 
The ethical and feasibility problems of ESCs based treatment in neurodegenerative disease 
are also expected to be solved in near future. The success in iPSCs seems to offer the 
advantages of hESCs without the ethical and rejection problems, although the iPSCs is not 
as versatile and plastic as ESCs. Revazova and collegues have established four unique HLA-
homozygous human ESCs lines which have a simple genetic profile in the critical areas of 
the DNA that code for immune rejection, these ES cell lines will not provoke an immune 
reaction in large segments of the population and could serve to create a stem cell bank as a 
renewable source of transplantable cells for use in cell therapy to treat degenerative diseases 
(Revazova et al., 2008).  
In conclusion, although there is still a long way to go in ESCs replacement therapy to 
become a clinical reality for AD, PD, HD and ALS, this therapeutic approach is promising 
for neurodegenerative diseases.  
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